- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00088946
Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer
Parallel, Randomized, Double-Blind, Placebo Controlled Phase II Adjuvant Studies of Erlotinib and Polyphenon E to Prevent the Recurrence and Progression of Tobacco-Related, Superficial Bladder Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Green tea extract (Polyphenon® E) contains certain ingredients that may slow the growth of tumor cells and prevent the recurrence of cancer. Giving erlotinib or green tea extract after surgery may kill any remaining tumor cells and may prevent the recurrence of bladder cancer.
PURPOSE: This randomized phase II trial is studying how well giving erlotinib together with green tea extract works in preventing cancer recurrence in former smokers who have undergone surgery for bladder cancer.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
Primary
- Compare the effects of erlotinib vs green tea extract (Polyphenon® E) vs placebo on the 2-year recurrence rate in former smokers with resected superficial transitional cell carcinoma of the bladder.
- Develop an effective chemopreventative strategy (as an adjunct to standard care) for the medical management of superficial bladder cancer in these patients.
Secondary
- Determine the toxic effects associated with these drugs in these patients.
- Determine a safe and effective chemopreventative dose of erlotinib in these patients.
- Correlate the modulation of 1 or more biomarkers with bladder cancer recurrence and/or progression in patients treated with these drugs.
- Determine the risk of clinical bladder cancer progression in patients treated with these drugs.
OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to disease stage (Ta vs T1 vs carcinoma in situ) and participating center. Patients are randomized to 1 of 3 treatment arms.
- Arm I: Patients receive oral erlotinib and oral green tea extract (Polyphenon® E) placebo once daily.
- Arm II: Patients receive oral green tea extract (Polyphenon® E) and oral erlotinib placebo once daily.
- Arm III: Patients receive oral erlotinib placebo and oral green tea extract placebo once daily.
In all arms, treatment continues for 12 months in the absence of disease recurrence or unacceptable toxicity.
Patients are followed every 3 months for 2 years and then every 6 months for 3 years.
PROJECTED ACCRUAL: A total of 330 patients (110 per treatment arm) will be accrued for this study within 3 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85032
- Bladder Cancer Genitourinary Oncology, PC
-
-
California
-
Los Angeles, California, United States, 90095-1781
- Jonsson Comprehensive Cancer Center at UCLA
-
Los Angeles, California, United States, 90073
- Veterans Affairs Medical Center - West Los Angeles
-
Santa Monica, California, United States, 90404
- Santa Monica UCLA Medical Center
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants must be former smokers and have ceased smoking at study entry.
Participants with any previous history of prior cancer diagnosis of Grade 1, 2, or 3, Ta or T1 papillary TCC, or CIS TCC, histologically confirmed, with a newly diagnosed or recurrent tumor within 6 months of accrual who are rendered disease free by standard of care. Patients with Grade 1 papillary tumors must meet at least one of the following additional criteria:
- multiple, synchronous tumors (>2)
- a single tumor greater than 1 cm in size
- At study entry, patients must have no evidence of disease
- Participants may have been previously treated with intravesical therapy.
- Age>18 years
- Transurethral resection of bladder tumor within 6 months prior to entry on to study
- Participants must have a signed written informed consent
- Agreement with complete abstinence from heterosexual intercourse or with the use of contraception during the treatment phase in women of childbearing potential
- Negative pregnancy test in women of childbearing potential
- Patients must have adequate bone marrow function at study entry (WBC>3000, platelets>100000/mm3, and hemoglobin>10g/dl)
- Patients must have satisfactory renal and hepatic function, defined as plasma creatinine of < 1.5mg/dl, total bilirubin < 1.5, and AST/ALT < 1.5 x the upper limit of normal
- Patients with evidence of obstructive lung disease as the etiology of a low diffusing capacity will still be eligible as long as the chest radiograph does not demonstrate interstitial changes
Exclusion Criteria:
- Prior chemotherapy or radiotherapy
- Prior (within 2 years) or concurrent malignancies, except non-melanomatous skin tumors or carcinoma in situ of the cervix
- Significant medical or psychiatric condition that would make the participant a poor protocol candidate
- TCC greater than or equal to T2 at most recent diagnosis
- Involvement of the upper urinary tract prior to or at the time of initial tumor resection
- Prior treatment with experimental drugs, high dose steroids, or with any other cancer treatment within 4 weeks prior to the first dose of study drug and for the duration of the study
- Positive pregnancy test at any time throughout the course of the study
- Normal consumption of greater than 5 cups of green tea daily
- Participants taking a known CYP 3A4 inducer or food products and medications known to be inhibitors or metabolized by CYP3A4/5 such as erythromycin, ketoconazole, etc. will be excluded since these drugs may be expected to result in altered exposure of Erlotinib
- ECOG performance status > 1
- History of idiopathic pulmonary fibrosis or other interstitial lung disease
- Use of tricyclic antidepressants, including imipramine, dothiepin, and mianserin
- Use within the last 12 months of amiodarone, methotrexate, isoniazid, minocycline, or nitrofurantoin
- History of environmental or occupational metal dust or wood dust exposure
- History of connective tissue disease, including scleroderma, rheumatoid arthritis, Sjogren's Syndrome, or sarcoid
- Significant ophthalmologic abnormalities or patients using contact lenses
- Evidence of interstitial lung disease on chest radiograph
Patients without obvious interstitial lung disease on chest radiograph will be excluded if they have evidence of parenchymal restrictive lung disease on pulmonary function testing as identified by the following criteria:
- Both vital capacity and total lung capacity <80% of predicted value
- A diffusing capacity of the lung for carbon monoxide, corrected for hemoglobin, < 75% of predicted value
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Arm 1
Polyphenon E plus erlotinib placebo daily for 12 months.
|
4-200mg capsules PO daily for 12 months
Other Names:
identical to Erlotinib in look and appearance of dosing.
|
EXPERIMENTAL: Arm 2
Erlotinib and Polyphenon E placebo daily for 12 months.
|
100 mg PO daily for 12 months
Other Names:
identical to Polyphenon E in look and appearance of dosing.
|
PLACEBO_COMPARATOR: Arm 3
Erlotinib placebo and Polyphenon E placebo daily for 12 months.
|
identical to Erlotinib in look and appearance of dosing.
identical to Polyphenon E in look and appearance of dosing.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluate the effects of a daily oral dose of polyphenon E, erlotinib, or placebo on subjects who are former smokers with a history of superficial bladder cancer on the bladder cancer recurrence rate at two years of any stage or grade of bladder cancer.
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To address the unmet need in medical management of superficial bladder cancer as an adjunct to standard of care.
Time Frame: 2 years
|
2 years
|
Assess toxicities associated with daily oral dosing of polyphenon E or erlotinib in subjects at risk for bladder tumor recurrence and to define a safe and effective prevention dose of erlotinib.
Time Frame: 2 years
|
2 years
|
Correlate the modulation of one or more biomarkers with recurrence of bladder cancer confirming the value as a surrogate endpoint biomarker for bladder cancer recurrence and/or progression.
Time Frame: 2 years
|
2 years
|
To assess the risk of clinical bladder cancer progression in patients treated with polyphenon E, erlotinib or placebo.
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Urologic Diseases
- Urinary Bladder Diseases
- Disease Attributes
- Recurrence
- Urinary Bladder Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Erlotinib Hydrochloride
Other Study ID Numbers
- CDR0000377681
- UCLA-0301091-03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bladder Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage III Bladder Cancer | No Evidence of Disease | Stage II Bladder Cancer | Stage IVA Bladder Cancer | Stage IVB Bladder CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteCompletedMuscle-Invasive Bladder Carcinoma | Bladder Cancer Stage II | Bladder Cancer Stage III | Bladder Cancer Stage IVUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnRecurrent Bladder Cancer | Urinary Complications | Stage 0 Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder Cancer
-
Fox Chase Cancer CenterTerminatedStage III Bladder Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Squamous Cell Carcinoma of the Bladder | Urethral Cancer Associated With Invasive Bladder Cancer | Stage II Bladder CancerUnited States
-
National Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
National Cancer Institute (NCI)TerminatedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Bladder Urothelial Carcinoma | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Stage II Bladder CancerUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Bristol-Myers SquibbRecruitingUrinary Bladder Cancer | Invasive Bladder CancerNetherlands
-
Taris Biomedical LLCBristol-Myers SquibbTerminatedBladder Cancer TNM Staging Primary Tumor (T) T2 | Bladder Cancer TNM Staging Primary Tumor (T) T2A | Bladder Cancer TNM Staging Primary Tumor (T) T2B | Bladder Cancer TNM Staging Primary Tumor (T) T3 | Bladder Cancer TNM Staging Primary Tumor (T) T3A | Bladder Cancer TNM Staging Primary Tumor... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingStage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8United States
Clinical Trials on Polyphenon E
-
Louisiana State University Health Sciences Center...Polyphenon PharmaCompleted
-
MediGeneCompletedCondylomata AcuminataUnited States, Argentina, Chile, Colombia, Mexico, Peru, Romania
-
Louisiana State University Health Sciences Center...Columbia UniversityCompletedBreast CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Completed
-
University of ChicagoTerminatedDuctal Carcinoma in SituUnited States
-
University of LouisvilleNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedMild to Moderately Active Ulcerative ColitisUnited States
-
Sherry ChowNational Cancer Institute (NCI)CompletedLung Cancer PreventionUnited States
-
Frank MeyskensNational Cancer Institute (NCI)TerminatedNon-melanomatous Skin CancerUnited States
-
Centre Hospitalier Universitaire de NiceCompletedEpidermolysis Bullosa DystrophicaFrance
-
Louisiana State University Health Sciences Center...National Center for Complementary and Integrative Health (NCCIH)Completed